In 2016, four new anticancer drugs were approved by the FDA, and a further 12 existing agents were approved for 14 additional indications. Each one of these drugs is associated with important clinical benefits, but at an average monthly cost of ∼US$9,000. Here, I discuss the cost–benefit considerations related to these treatments and contemplate future economic prospects.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Savage, P. & Mahmoud, S. Development and economic trends in cancer therapeutic drugs: a 5-year update 2010–2014. Br. J. Cancer 112, 1037–1041 (2015).
Light, D. W. & Kantarjian, H. Market spiral pricing of cancer drugs. Cancer 119, 3900–3902 (2013).
Kantarjian, H., Steensma, D., Rius, S. J., Elshaug, A. & Light, D. High cancer drug prices in the United States: reasons and proposed solutions. J. Oncol. Pract. 10, e208–e211 (2014).
US Food and Drug Administration. Hematology/oncology (cancer) approvals and safety notifications. FDA http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm (2016).
Stilgenbauer, S. et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 17, 768–778 (2016).
Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016).
Tap, W. D. et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 388, 488–497 (2016).
US Food and Drug Administration. Highlights of prescribing information for RUBRACA. FDA http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209115s000lbl.pdf (2016).
Kaufman, B. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 20, 244–250 (2015).
Dimopoulos, M. A. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 1319–1331 (2016).
Palumbo, A. et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 754–366 (2016).
Truven Health Analytics. Red book, a comprehensive, consistent drug pricing resource. Micromedex http://micromedex.com/products/product-suites/clinical-knowledge/redbook (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Savage, P. Approvals in 2016: cost–benefit challenges of new anticancer agents. Nat Rev Clin Oncol 14, 133–134 (2017). https://doi.org/10.1038/nrclinonc.2017.12
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.12
This article is cited by
-
Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?
Current Hematologic Malignancy Reports (2019)
